Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 97,109 |
|
|||||
| News | - | ||||||
| Day High | 2.03 | Low High |
|||||
| Day Low | 1.90 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Cognition Therapeutics Inc | CGTX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.04 | 2.09% | 1.95 | 18:33:09 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.92 | 1.90 | 2.03 | 1.95 | 1.91 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 513 | 97,109 | US$ 1.95 | US$ 189,692 | - | 0.9001 - 3.49 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 16:30:27 | 58 | US$ 1.98 | USD |
Cognition Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 59.62M | 30.42M | - | 0 | -25.79M | -0.85 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Cognition Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/11/2024 | 15:11 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/11/2024 | 15:06 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 2/20/2024 | 15:44 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/20/2024 | 15:13 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/20/2024 | 15:13 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/09/2024 | 18:12 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 1/19/2024 | 14:07 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
| 1/08/2024 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 1/08/2024 | 15:11 | Edgar (US Regulatory) | Form 424B4 - Prospectus [Rule 424(b)(4)] |
| 1/04/2024 | 15:21 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/04/2024 | 06:30 | GlobeNewswire Inc. | Cognition Therapeutics CEO Issues Letter to Shareholders |
| 12/29/2023 | 15:02 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CGTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.00 | 2.10 | 1.85 | 1.95 | 87,751 | -0.05 | -2.50% |
| 1 Month | 1.82 | 2.1599 | 1.79 | 1.97 | 126,432 | 0.13 | 7.14% |
| 3 Months | 2.20 | 2.45 | 1.75 | 1.95 | 208,204 | -0.25 | -11.36% |
| 6 Months | 1.08 | 2.79 | 0.9001 | 1.89 | 192,128 | 0.87 | 80.56% |
| 1 Year | 1.73 | 3.49 | 0.9001 | 1.91 | 156,633 | 0.22 | 12.72% |
| 3 Years | 12.15 | 13.80 | 0.9001 | 3.09 | 164,335 | -10.20 | -83.95% |
| 5 Years | 12.15 | 13.80 | 0.9001 | 3.09 | 164,335 | -10.20 | -83.95% |
Cognition Therapeutics Description
| Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. |
